Plain-English translation of NCT04792489 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a treatment called MB-CART2019.1, which is made from your own immune cells that have been genetically engineered in a laboratory to recognize and fight cancer cells. The medication is designed to attack blood cancers that have come back after previous treatments or that didn't respond to earlier therapy. Researchers will collect your immune cells, engineer them to be better cancer fighters, grow more of them in the lab, and then put them back into your body through an infusion.
Many patients with aggressive blood cancers like diffuse large B-cell lymphoma run out of standard treatment options after their cancer returns or stops responding to chemotherapy. This medication was created to offer a new hope for patients whose cancers are hard to treat, by harnessing the power of their own immune system to fight the disease.
You likely qualify if…
You likely don't qualify if…
First, you'll undergo screening tests to confirm you're eligible. Then, doctors will collect some of your blood cells in a procedure called leukapheresis (similar to donating blood but done at a special center). While your cells are being engineered in the laboratory over several weeks, you'll receive chemotherapy to prepare your body. Once your engineered cells are ready, you'll receive them back as an infusion through an IV. You'll then be followed closely in the hospital and clinic for safety monitoring, with visits continuing for up to 2 years to track how well the treatment works and how you're feeling.
AI-generated summary from trial data · Jul 18, 2026 · Not medical advice
United States